Swedish Orphan Biovitrum AB (Sobi)(STO:SOBI) and Dova Pharmaceuticals Inc (Dova) (Nasdaq:DOVA) announced on Tuesday that Sobi has completed its acquisition of Dova.

Following the completion of Sobi's successful tender offer to purchase outstanding shares of Dova, Sobi acquired all remaining shares of Dova through a merger pursuant to Section 251(h) of the General Corporation Law of the State of Delaware.

This tender offer by Sobi was for USD27.50 per share, net to the seller thereof in cash, without interest and subject to any applicable withholding taxes, plus one non-transferable Contingent Value Right (CVR), which entitles Dova shareholders to an additional USD1.50 per share upon approval of Doptelet for use in Chemotherapy-Induced Thrombocytopenia by the US Food and Drug Administration.

As a result of the transaction, Dova has now become an indirect wholly owned subsidiary of Sobi.

At the effective time of the merger, and subject to any perfected appraisal rights, all of the remaining shares of Dova common stock not purchased in the tender offer were converted into the right to receive the same USD27.50 per share, net in cash, without interest and subject to any applicable withholding taxes, plus one non-transferrable CVR that was paid in connection with the tender offer.

This transaction is valued at up to USD915m on a fully diluted basis.

Sobi is a specialised international biopharmaceutical company that aims to transform the lives of people with rare diseases. It provides sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications.